Radiation Plus Glofitamab for Hard-to-Treat B-Cell Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with relapsed or refractory CD20+ diffuse large B-cell lymphoma (DLBCL) confirmed by biopsy
- You have received at least 2 prior lines of cancer treatment, or 1 line plus a stem cell transplant (and you're not eligible for CAR-T therapy)
- You have measurable, active lymphoma visible on a PET scan that can be safely treated with radiation
- Your blood counts, kidney function, liver function, and heart function meet minimum safe levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to treating aggressive B-cell lymphomas that have returned or didn't respond to initial chemotherapy. It combines a drug called glofitamab with CAR-T cell therapy (immune cells engineered in the lab to fight cancer) to see if it improves outcomes for patients who are candidates for this advanced treatment.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a combination of radiation therapy, lenalidomide, and glofitamab for people with a type of lymphoma called DLBCL that has not responded to or has returned after initial treatment. The goal is to see if this combination can help when other treatments have failed.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
Hear when a new Relapsed /Refractory DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.